Overview and Scope
A neurological biomarker is a substance that provides objective and quantifiable information about the presence, progression, or characteristics of a neurological disorder or condition. They are used in clinical practice during drug development.
Sizing and Forecast
The neurological biomarkers market size has grown rapidly in recent years. It will grow from $9.46 billion in 2023 to $10.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, aging population, drug development needs, increased funding for neurological research, personalized medicine.
The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $17.18 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to biomarkers for early detection, biosensors, wearable devices, global health initiatives, patient-centric approach. Major trends in the forecast period include technological innovation in imaging, rapid advances in omics technologies, integration of artificial intelligence (ai), real-world evidence in biomarker validation, advancements in diagnostic technologies, collaboration between industry and research institutions.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report
Segmentation & Regional Insights
The neurological biomarkers market covered in this report is segmented –
1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products
2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users
North America was the largest region in the neurological biomarkers market in 2023. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of neurological diseases is expected to propel the growth of the neurological biomarker market going forward. Neurological illnesses affect the brain, spinal cord, and all of the body’s other nerves. Parkinson’s disease is a neurodegenerative disorder affecting the neurological system and the areas of the body that are under the control of the nerves. Neurological biomarkers help provide an early diagnosis of Parkinson’s disease using pathological, biochemical, and genetic testing. For instance, in December 2022, according to the Parkinson’s Foundation, a US-based non-profit organization, the number of new diagnoses of Parkinson’s disease reached 90,000 in 2022, up from 60,000 per year in 2021. Therefore, the increasing prevalence of neurological diseases is driving the growth of the neurological biomarker market.
Key Industry Players
Major companies operating in the neurological biomarkers market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.
The neurological biomarkers market report table of contents includes:
1. Executive Summary
2. Neurological Biomarkers Market Characteristics
3. Neurological Biomarkers Market Trends And Strategies
4. Neurological Biomarkers Market – Macro Economic Scenario
5. Global Neurological Biomarkers Market Size and Growth
.
32. Global Neurological Biomarkers Market Competitive Benchmarking
33. Global Neurological Biomarkers Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Neurological Biomarkers Market
35. Neurological Biomarkers Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
